The goal of this grant is to further develop the novel recombinant vector, Newcastle disease virus (NDV), so that it can be used as a platform to vaccinate humans against bioterrism agents and emerging infectious diseases. An advantage of this strategy is that vaccines for emerging diseases can be quickly made by inserting a protein of the pathogen into the NDV genome. For this grant we will focus on developing vaccines to three dangerous pathogens: potential pandemic influenza virus, Nipah virus, and Chikungunya virus. We will test several different strategies to improve rNDV vaccines. Though NDV has already been safely administered to humans, we will develop single-cycle vaccines that do not spread beyond the initially infected cells. Since these vaccines cannot spread throughout the host, they could be administered safely to immunocompromised individuals. We will develop bi- and triple-segmented rNDV vaccines that are able to express two or three foreign proteins. These viruses will induce a broader immune response compared to recombinant vaccines expressing just one protein of a foreign pathogen. We will also identify the NDV RNA packaging signals and incorporate these signals into the multiple-segmented rNDV vaccines to increase the efficiency of packaging multiple segments into the same virion. One problem with vaccine development is that vaccines are often not very effective in the aged population and strategies are needed to enhance vaccine protection in this group. We will determine whether an adjuvant that stimulates NKT cells, alpha-C-galactosylceramide, can enhance the immunogenicity of the NDV vaccines in both young and aged mice. Another strategy to enhance immunogenicity to rNDV vaccines includes re-targeting the rNDV vaccines to dendritic cells, which is the site of the initiation of the adaptive immune response. This will be accomplished by expressing a single-chain antibody to dendritic cell receptor, DEC-205, from the rNDV genome. We will collaborate with NBC investigator Dr. John Rose to determine whether prime-boost regimens involving vaccinating mice with rNDV expressing influenza virus HA protein and boosting with rVSV expressing influenza virus HA protein can enhance the immune response to influenza virus HA better than either vector alone. To determine whether the vaccines are protective, we will challenge mice with influenza H5N1 at Mount Sinai and collaborate with other RCE investigators to challenge animals vaccinated with Nipah and Chikungunya rNDV vaccines.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Johnson, Joshua C; Martinez, Osvaldo; Honko, Anna N et al. (2014) Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 107:102-9
Gough, Daniel J; MariƩ, Isabelle J; Lobry, Camille et al. (2014) STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 124:2252-61
Kazakov, Teymur; Kuznedelov, Konstantin; Semenova, Ekaterina et al. (2014) The RimL transacetylase provides resistance to translation inhibitor microcin C. J Bacteriol 196:3377-85
Rajsbaum, Ricardo; Garcia-Sastre, Adolfo; Versteeg, Gijs A (2014) TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 426:1265-84
Lo, Michael K; Bird, Brian H; Chattopadhyay, Anasuya et al. (2014) Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101:26-9
Mackow, Erich R; Dalrymple, Nadine A; Cimica, Velasco et al. (2014) Hantavirus interferon regulation and virulence determinants. Virus Res 187:65-71
Varshney, Avanish K; Wang, Xiaobo; Aguilar, Jorge L et al. (2014) Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio 5:e01007-14
Chung, Lawton K; Philip, Naomi H; Schmidt, Valentina A et al. (2014) IQGAP1 is important for activation of caspase-1 in macrophages and is targeted by Yersinia pestis type III effector YopM. MBio 5:e01402-14
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Szaba, Frank M; Kummer, Lawrence W; Duso, Debra K et al. (2014) TNF? and IFN? but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection. PLoS Pathog 10:e1004142

Showing the most recent 10 out of 549 publications